1.72
price down icon1.71%   -0.03
pre-market  Vorhandelsmarkt:  1.74   0.02   +1.16%
loading
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
2.42M
Relative Volume:
1.17
Marktkapitalisierung:
$390.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-179.82M
KGV:
-1.2932
EPS:
-1.33
Netto-Cashflow:
$-159.16M
1W Leistung:
+18.62%
1M Leistung:
+19.44%
6M Leistung:
+90.69%
1J Leistung:
+62.26%
1-Tages-Spanne:
Value
$1.6701
$1.755
1-Wochen-Bereich:
Value
$1.47
$1.90
52-Wochen-Spanne:
Value
$0.6617
$1.90

Gossamer Bio Inc Stock (GOSS) Company Profile

Name
Firmenname
Gossamer Bio Inc
Name
Telefon
(858) 684-1300
Name
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Name
Mitarbeiter
145
Name
Twitter
@GossamerBio
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
GOSS's Discussions on Twitter

Vergleichen Sie GOSS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GOSS
Gossamer Bio Inc
1.72 329.59M 0 -179.82M -159.16M -1.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-14 Eingeleitet Scotiabank Sector Outperform
2024-06-25 Eingeleitet Oppenheimer Outperform
2024-04-05 Fortgesetzt Wedbush Outperform
2023-07-27 Herabstufung UBS Buy → Neutral
2023-03-07 Herabstufung Raymond James Outperform → Mkt Perform
2023-03-01 Eingeleitet Guggenheim Neutral
2022-12-07 Herabstufung Barclays Overweight → Equal Weight
2022-12-07 Herabstufung JP Morgan Neutral → Underweight
2022-12-07 Herabstufung SMBC Nikko Outperform → Neutral
2022-10-20 Eingeleitet Goldman Buy
2022-09-21 Eingeleitet JP Morgan Neutral
2022-09-19 Eingeleitet Wedbush Outperform
2022-04-18 Eingeleitet Raymond James Outperform
2022-04-06 Eingeleitet UBS Buy
2022-01-10 Hochstufung SMBC Nikko Neutral → Outperform
2021-11-09 Fortgesetzt Cantor Fitzgerald Overweight
2021-09-21 Fortgesetzt Piper Sandler Overweight
2020-06-29 Eingeleitet H.C. Wainwright Buy
2020-04-22 Eingeleitet Piper Sandler Overweight
2020-02-27 Eingeleitet Barclays Overweight
2019-12-03 Fortgesetzt BofA/Merrill Buy
2019-10-30 Eingeleitet Berenberg Buy
2019-03-05 Eingeleitet Barclays Overweight
2019-03-05 Eingeleitet BofA/Merrill Buy
2019-03-05 Eingeleitet Evercore ISI Outperform
2019-03-05 Eingeleitet SVB Leerink Outperform
Alle ansehen

Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Gossamer Bio Inc. stock priceTremendous portfolio expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Gossamer Bio Inc. stock attracts strong analyst attentionBig Return Stock Tips - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Gossamer Bio Inc. stock price move sharplyLow Volatility High Yield Stocks - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Gossamer Bio Inc. stockRapidly growing investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

Is Gossamer Bio Inc. a good long term investmentTremendous growth opportunities - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Gossamer Bio Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 15, 2025

How Gossamer Bio Inc. stock performs during market volatilityShort Term Risk Controlled Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

GOSS’s Stock Market Adventure: 30.77% YTD Growth Amidst Volatility - investchronicle.com

Jul 15, 2025
pulisher
Jul 14, 2025

Scotiabank Initiates Gossamer Bio at Sector Outperform With $11 Price Target - MarketScreener

Jul 14, 2025
pulisher
Jul 03, 2025

Gossamer Bio (NASDAQ:GOSS) Shares Down 3.2% – Time to Sell? - Defense World

Jul 03, 2025
pulisher
Jun 30, 2025

Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell Microcap Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Gossamer Bio Approves 2019 Incentive Award Plan - TipRanks

Jun 25, 2025
pulisher
Jun 24, 2025

Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib - Insider Monkey

Jun 24, 2025
pulisher
Jun 16, 2025

Gossamer Bio Announces Completion of Enrollment in Registrationa - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Gossamer Bio (GOSS) Wraps Up Enrollment for Phase 3 PAH Study | GOSS Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - The Joplin Globe

Jun 16, 2025
pulisher
Jun 16, 2025

Gossamer Bio's Breakthrough PAH Drug Hits Major Milestone: 390 Patients Enrolled in Phase 3 Trial - Stock Titan

Jun 16, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Brokers Offer Predictions for Gossamer Bio FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GOSS Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 06, 2025
pulisher
May 26, 2025

HC Wainwright Increases Earnings Estimates for Gossamer Bio - Defense World

May 26, 2025
pulisher
May 22, 2025

Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings - Defense World

May 22, 2025
pulisher
May 20, 2025

Analyze Gossamer Bio Inc (NASDAQ: GOSS) Before Investing. - Stocksregister

May 20, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

May 19, 2025
pulisher
May 18, 2025

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript - MSN

May 18, 2025
pulisher
May 18, 2025

Wedbush Reiterates “Outperform” Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World

May 18, 2025
pulisher
May 18, 2025

The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00 - Defense World

May 18, 2025
pulisher
May 17, 2025

GOSS Stock Update: Analyst Reiterates Outperform Rating | GOSS S - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks

May 16, 2025
pulisher
May 16, 2025

Gossamer Bio (GOSS): Goldman Sachs Raises Price Target to $8.00 - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Cantor Fitzgerald maintains Overweight on Gossamer Bio stock By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Cantor Fitzgerald maintains Overweight on Gossamer Bio stock - Investing.com

May 16, 2025

Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):